Right. Some of the published material also said that Adrenaclick was not therapeutically equivalent to EpiPen.
It's opaque. There isn't a transparency, and some it is this idea of proprietary knowledge.
That was a reaction to the contaminated steroid injections that happened at the company--what, up in Massachusetts or so...
It's kind of hard to get bureaucrats out of Washington.
Maybe we should expedite things when there's only one person making something and the price goes up at an alarming pace.
The overarching question we have to ask is: Does the FDA care about drug prices?
I like the idea of maybe starting a generic application process before it expires.
Thank you. That reminds me of one more question for Philip.
I kind of wanted to broaden the debate beyond EpiPen.
I guess what we have to look at is in the mission that the FDA is given--are they going in and--have we increased inspec...
Maybe we should stop that--stop allowing a patent for that, because there is some discussion--like I remember in ophthal...